Could the same medication that causes people to lose weight hold the key to reducing drinking? In a new paper at the European ...

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of semaglutide ...

Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration ...

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

Researchers reviewed the clinical characteristics of patients taking GLP-1 receptor agonists who develop NAION.

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is losing ground.

Weight loss drugs are getting more popular, even for teenagers and pre-teens -- but while many doctors have reported ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 - covering burden, and the value of treatment and prevention ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...